NO20005632D0 - Antistoffer mot CD 23, derivater derav og deres terapeutiske anvendelse - Google Patents

Antistoffer mot CD 23, derivater derav og deres terapeutiske anvendelse

Info

Publication number
NO20005632D0
NO20005632D0 NO20005632A NO20005632A NO20005632D0 NO 20005632 D0 NO20005632 D0 NO 20005632D0 NO 20005632 A NO20005632 A NO 20005632A NO 20005632 A NO20005632 A NO 20005632A NO 20005632 D0 NO20005632 D0 NO 20005632D0
Authority
NO
Norway
Prior art keywords
antibodies
derivatives
therapeutic use
therapeutic
Prior art date
Application number
NO20005632A
Other languages
English (en)
Other versions
NO20005632L (no
Inventor
Jean-Yves Marcel Paul Bonnefoy
Scott James Crowe
Jonathan Henry Ellis
Nicholas Timothy Rapson
Jean Shearin
Original Assignee
Glaxo Wellcome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Ltd filed Critical Glaxo Wellcome Ltd
Publication of NO20005632D0 publication Critical patent/NO20005632D0/no
Publication of NO20005632L publication Critical patent/NO20005632L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20005632A 1998-05-09 2000-11-08 Antistoffer mot CD23, derivater derav og deres terapeutiske anvendelse NO20005632L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9809839.5A GB9809839D0 (en) 1998-05-09 1998-05-09 Antibody
PCT/GB1999/001434 WO1999058679A1 (en) 1998-05-09 1999-05-07 Antibodies to cd23, derivatives thereof, and their therapeutic uses

Publications (2)

Publication Number Publication Date
NO20005632D0 true NO20005632D0 (no) 2000-11-08
NO20005632L NO20005632L (no) 2001-01-08

Family

ID=10831668

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005632A NO20005632L (no) 1998-05-09 2000-11-08 Antistoffer mot CD23, derivater derav og deres terapeutiske anvendelse

Country Status (25)

Country Link
US (1) US7008623B1 (no)
EP (1) EP1076701A1 (no)
JP (1) JP2002514421A (no)
KR (1) KR20010043470A (no)
CN (1) CN1308676A (no)
AP (1) AP1547A (no)
AU (1) AU763491B2 (no)
BR (1) BR9910327A (no)
CA (1) CA2328606A1 (no)
EA (1) EA200001041A1 (no)
EE (1) EE200000658A (no)
GB (1) GB9809839D0 (no)
HR (1) HRP20000762A2 (no)
HU (1) HUP0102005A3 (no)
ID (1) ID28088A (no)
IL (1) IL139384A0 (no)
IS (1) IS5696A (no)
NO (1) NO20005632L (no)
NZ (1) NZ507879A (no)
PL (1) PL344019A1 (no)
SK (1) SK16762000A3 (no)
TR (1) TR200003281T2 (no)
WO (1) WO1999058679A1 (no)
YU (1) YU69000A (no)
ZA (1) ZA200006312B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
TR200300478T2 (tr) 2000-10-13 2004-10-21 Biogen Inc. Hümanize antiLT-ß-R antikorları
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
EP1539793A4 (en) * 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
JP2007521248A (ja) * 2003-12-10 2007-08-02 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヒト化抗ｃｃｒ２抗体および該抗体を使用する方法
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
EP1799260A4 (en) * 2004-09-29 2011-09-28 Centocor Inc ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, TECHNIQUES AND USES
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
ES2433251T5 (es) 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US7680868B2 (en) * 2005-12-20 2010-03-16 Roche Molecular Systems, Inc. PCR elbow determination by use of a double sigmoid function curve fit with the Levenburg-Marquardt algorithm and normalization
EP1804172B1 (en) * 2005-12-20 2021-08-11 Roche Diagnostics GmbH PCR elbow determination using curvature analysis of a double sigmoid
WO2009043051A2 (en) * 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
EP2222709B1 (en) 2007-11-30 2016-11-23 Glaxo Group Limited Antigen-binding constructs
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
UY31807A (es) 2008-05-06 2009-12-14 Glaxo Group Ltd Encapsulación de agentes biológicamente activos
US20110305692A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Antigen-binding contructs
EP2401297A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Antigen-binding constructs
CA2753263A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
US20120058116A1 (en) 2009-04-24 2012-03-08 Andrew Beaton Fgfr1c antibody combinations
ES2912569T3 (es) 2009-08-28 2022-05-26 Teva Pharmaceuticals Int Gmbh Métodos para tratar el dolor visceral administrando anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de la calcitonina
FR2957598B1 (fr) 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
EP2643352B1 (en) 2010-11-23 2018-05-02 Glaxo Group Limited Antigen binding proteins to oncostatin m (osm)
SG190362A1 (en) 2010-11-24 2013-06-28 Glaxo Group Ltd Multispecific antigen binding proteins targeting hgf
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
SI3415531T1 (sl) 2011-05-27 2023-12-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) - vezni proteini
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
US10176293B2 (en) 2012-10-02 2019-01-08 Roche Molecular Systems, Inc. Universal method to determine real-time PCR cycle threshold values
US10280221B2 (en) 2013-03-15 2019-05-07 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
EP3019525B1 (en) * 2013-07-10 2019-04-17 Onconox ApS Antibodies to beta2-glycoprotein i and therapeutic uses thereof
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2018002610A (es) 2015-09-02 2018-09-27 Immutep Sas Anticuerpos anti-lag-3.
JP6935184B2 (ja) * 2016-05-31 2021-09-15 シスメックス株式会社 糖ペプチドと反応するモノクローナル抗体およびその用途
US10479827B2 (en) 2016-05-31 2019-11-19 Sysmex Corporation Monoclonal antibody reacting with glycopeptide, and use thereof
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
EP3740198A4 (en) 2018-01-18 2023-08-09 Fred Hutchinson Cancer Center MODIFICATION OF INFLAMMATORY STATES OF IMMUNE CELLS IN VIVO BY MODULATION OF CELL ACTIVATION STATES
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
KR20220026585A (ko) 2019-06-26 2022-03-04 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Il1rap 결합 단백질
CN112552403A (zh) * 2020-12-25 2021-03-26 南京英瀚斯生物科技有限公司 一种人源抗人CD23抗体的Fab片段、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ATE327331T1 (de) 1991-07-25 2006-06-15 Biogen Idec Inc Rekombinante antikörper zur humanen therapie
CA2203363A1 (en) * 1994-10-25 1996-05-02 Jean-Yves Marcel Paul Bonnefoy Binding agents to cd23
US6011138A (en) 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies

Also Published As

Publication number Publication date
EE200000658A (et) 2002-04-15
CN1308676A (zh) 2001-08-15
HUP0102005A3 (en) 2003-10-28
IS5696A (is) 2000-10-31
HUP0102005A2 (hu) 2001-10-28
AP2000001983A0 (en) 2000-12-31
BR9910327A (pt) 2001-01-30
NZ507879A (en) 2004-02-27
EP1076701A1 (en) 2001-02-21
YU69000A (sh) 2003-08-29
WO1999058679A1 (en) 1999-11-18
ZA200006312B (en) 2003-02-26
GB9809839D0 (en) 1998-07-08
KR20010043470A (ko) 2001-05-25
PL344019A1 (en) 2001-09-24
TR200003281T2 (tr) 2001-03-21
SK16762000A3 (sk) 2001-07-10
CA2328606A1 (en) 1999-11-18
AU3836799A (en) 1999-11-29
EA200001041A1 (ru) 2001-06-25
US7008623B1 (en) 2006-03-07
AU763491B2 (en) 2003-07-24
IL139384A0 (en) 2001-11-25
NO20005632L (no) 2001-01-08
JP2002514421A (ja) 2002-05-21
ID28088A (id) 2001-05-03
HRP20000762A2 (en) 2001-06-30
AP1547A (en) 2006-01-13

Similar Documents

Publication Publication Date Title
NO20005632L (no) Antistoffer mot CD23, derivater derav og deres terapeutiske anvendelse
DK0869126T3 (da) Dithiolanderivater, deres fremstilling og deres terapeutiske virkning
IS2277B (is) Meðferðarlegar bíarýl afleiður
NO954239L (no) Heterocykliske forbindelser og deres fremstilling og anvendelse
NO954369L (no) Oksazolidindionderivater, deres fremstilling og anvendelse
EE9900290A (et) 3-heterotsüklüül-asendatud bensoüülderivaadid
DK8189D0 (da) Antigen-antistof-konjugater, deres fremstilling og anvendelse
NO20003067L (no) Antipicornavirus-forbindelser og fremgangsmÕter for deres anvendelse og fremstilling
DK1019358T3 (da) 3,3-diarylpropylaminer, deres anvendelse og fremstilling
DK0871656T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
NO943682D0 (no) Imidazol-4-yl-piperidin-derivater, deres fremstilling og terapeutiske anvendelse
DK0873308T3 (da) O-Carbamoyl-phenylalaninol-forbindelser og deres farmaceutisk anvendelige salte
NO953673L (no) [1,2,4ÅTriazolo[4,3-aÅkinoksalinderivater, deres fremstilling og anvendelse
NO20001934D0 (no) 3-Substituerte tetrahydropyridopyrimidinon-derivater, deres fremstilling og anvendelse
NO992676D0 (no) 1,4-diazabicyklo[2,2,2]okt-2-ylmetylderivater, deres fremstilling og terapeutiske anvendelse
DK0835254T3 (da) Oxazolidinonderivater, deres fremstilling og deres terapeutiske anvendelse
NO962477L (no) Benzamidderivater, deres fremstilling og deres terapautiske anvendelse
NO940130D0 (no) Benzimidazolderivater, fremgangsmaate for deres fremstilling og te rapeutisk anvendelse derav
NO954763D0 (no) Piperidinderivater, deres fremstilling og anvendelse
NO20013085D0 (no) Fosfororganiske forbindelser og deres anvendelse
PT1178981E (pt) 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
NO955242D0 (no) Piperidinderivater, fremgangsmåte for fremstilling derav og deres terapeutiske anvendelse
NO984921D0 (no) Tienopyridinderivater og deres anvendelse
NO20000066D0 (no) 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse
NO981002D0 (no) Karboksylsyrederivater, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application